RBOT
Vicarious Surgical Inc.2.4300
-0.0400-1.62%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
FY Q3 '25
Outsourcing risks timeline; suturing surges
Q&A flagged potential disruptions to the year-end 2026 design freeze from outsourcing non-core elements like capital equipment, though management aims to mitigate via PA Consulting's end-November plan and timely updates. Surgeons in recent cadaver and synthetic labs showed dramatic suturing gains for IPOM ventral hernia, slashing average time from 40 to 14 minutes. A 15% headcount cut aids burn control alongside the fixed-fee consulting gig. Hospital partners remain engaged, with naive surgeons quickly performing procedures. Outsourcing execution matters next. Progress thrills, yet timeline slips loom.
Key Stats
Market Cap
16.48MP/E (TTM)
-Basic EPS (TTM)
-9.03Dividend Yield
0%Recent Filings
8-K
ATM launch, warrants suspended
Vicarious Surgical inked an ATM agreement on December 12, 2025, with H.C. Wainwright to sell up to $2.3M in Class A shares at market, paying 3% commissions. Warrants face immediate NYSE trading suspension due to low prices, while common stock continues unaffected. FY2026 cash burn guidance slashed to ~$35M, down $10M from 2025's $45M. Cost cuts drive progress.
8-K
Board shrinks, cash burn drops
Vicarious Surgical trimmed its board from nine to seven members on December 1, 2025, with Beverly Huss and Randy Clark resigning amicably amid a size reduction—no disagreements noted. It updated 2025 cash burn guidance to ~$45 million, a $5 million cut from prior $50 million, crediting cost controls. Board shuffled committees too. Leaner structure sharpens focus.
10-Q
Q3 FY2025 results
Vicarious Surgical narrowed its Q3 operating loss to $11.5M from $17.8M y/y, a crisp 35% cut driven by 26% lower R&D and 45% slimmer G&A, mainly from personnel efficiencies. Losses narrowed further to $39.7M YTD from $49.3M y/y (20% better), with EPS improving to $(1.86) from $(2.90) on 5.95M weighted shares—anti-dilution holds. Cash burned $35.8M in operations; quarter-end liquidity stood at $13.4M, bolstered by $5.2M October offering, yet runway ends Q1 2026. Cash is king here. NYSE listing hangs by a thread amid compliance woes.
8-K
Q3 expenses down 35%
Vicarious Surgical slashed Q3 operating expenses 35% to $11.5M from $17.8M year-over-year, driving GAAP net loss down to $11.1M ($1.86/share) versus $17.1M ($2.90/share). Cash burn hit $10.5M, with $13.4M in cash at quarter-end, bolstered by $5.9M from an October direct offering. Full-year 2025 cash burn guidance: ~$50M. Expenses dropped sharply.
8-K
Prices $5.9M offering
Vicarious Surgical priced a $5.9M registered direct offering on October 7, 2025, selling 588,300 shares and pre-funded warrants for 561,700 shares to one investor, plus Series A/B warrants for 1.15M shares each at $5.10 exercise price. Closing set for October 9; warrants need stockholder approval within 120 days. Cash bolsters working capital, yet dilutes shares while locking insiders for 30 days.
IPO
Employees
Sector
Industry
BSX
Boston Scientific Corporation
92.95+0.76
ISRG
Intuitive Surgical, Inc.
554.58-4.94
LNSR
LENSAR, Inc.
12.06+0.54
MBOT
Microbot Medical Inc.
2.22+0.01
MDT
Medtronic plc.
97.72-0.85
MGRM
Monogram Technologies Inc.
6.00+0.00
PRCT
PROCEPT BioRobotics Corporation
35.66-0.44
SERV
Serve Robotics Inc.
10.57-0.40
SSII
SS Innovations International In
5.50+0.41
VTAK
Catheter Precision, Inc.
2.19-0.04